New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
20:02 EDTMRKMerck announces interim results evaluating MK-5172 in HCV therapy
Merck announced interim results from a Phase II, multi-center, randomized, dose-ranging study (n=332) assessing the safety and antiviral activity of MK-5172, an investigational, once-daily, oral NS3/4A protease inhibitor for the treatment of chronic hepatitis C virus, HCV, genotype 1 infection in combination therapy in treatment-naïve patients. These data will be presented this week at the American Association for the Study of Liver Diseases Annual Meeting, AASLD. In the initial cohort, termed the "Vanguard Cohort," (n=136), 96 percent of patients (25/26) who received a regimen containing 100 mg QD of MK-5172 with PR achieved sustained virologic response, SVR, 12, defined as having undetectable virus (HCV RNA) 12 weeks after treatment ended, compared to 54 percent of patients (13/24) in the control arm. “We are excited by these interim results evaluating MK-5172 in combination therapy,” said Eliav Barr, M.D., vice president, Infectious Diseases, Project Leadership and Management, Merck Research Laboratories. “Our commitment to chronic hepatitis C remains steadfast. We look forward to continuing our studies of MK-5172, including in interferon-free regimens." Currently planned studies evaluating interferon-free regimens with MK-5172 will be dosed at 100 mg QD. .
News For MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
16:19 EDTMRKOn The Fly: Top stock stories for Friday
Stocks on Wall Street began the final trading day of May with slight losses. The averages began to pick up downside momentum after revised GDP numbers confirmed expectations that the economy shrank in the first quarter of the year. The Wall Street adage of “sell in May, then go away” appeared to be taking hold as the S&P broke a support level and took the other averages with it. Investors are now concerned about a June swoon, as it is historically one of the worst performing months of the year. ECONOMIC EVENTS: In the U.S., the second estimate of gross domestic product showed it shrank at a 0.7% seasonally adjusted annual rate in the first quarter. This was down from the previous estimate that output grew 0.2% from January through March, but better than the revision to a 1% decline that had been forecast by analysts. The Chicago PMI unexpectedly dropped 6.1 points to 46.2 in May, versus expectations for it to have risen to a reading of 53. The University of Michigan's consumer sentiment reading came in with a 90.7 reading for the final May print, which was up from the preliminary 88.6 reading for the month but down from April's 95.9 figure. COMPANY NEWS: Shares of Humana (HUM) jumped $36.24, or 20.31%, to $214.65 after The Wall Street Journal said the company has hired Goldman Sachs (GS) to help it explore a potential sale after receiving indications of takeover interest. Some of the Journal's sources reportedly said Aetna (AET) and Cigna (CI) are among possible bidders for Humana. Bloomberg then said Humana's sale exploration came after Cigna made a takeover approach. Leerink analyst Ana Gupte wrote in a note to investors on May 12 that consolidation in the industry remains likely, adding that a deal between Aetna and either Cigna or Humana were both "meaningfully accretive" and "imminent" possibilities. MAJOR MOVERS: Among the notable gainers was Heron Therapeutics (HRTX), which gained $7.41, or 60%, to $19.76 after the company reported positive top-line data from a Phase 3 marketing study looking at Sustol as part of a 3-drug regimen for the prevention of delayed-onset chemotherapy-induced nausea and vomiting following administration of highly emetogenic chemotherapy agents. Also higher was Altera (ALTR), which advanced $1.88, or 4%, to $48.85 after reports from The New York Post and Financial Times claimed the company is near a deal to be acquired by chipmaking giant Intel (INTC) for up to $54 per share. Reuters, meanwhile, revised its prior report to indicate the potential price of the deal could be close to $16B. Among the noteworthy losers was Abercrombie & Fitch (ANF), which fell $1.63, or 7.38%, to $20.47 after Janney Capital downgraded the stock to Sell from Hold and warned the company's comparative sales may continue to drop year-over-year as it changes nearly every aspect of its business. Also lower were shares of Bristol-Myers Squibb (BMY), which dropped $4.55, or 6.58%, to $64.60 after the company reported data from a Phase III study evaluating Opdivo in previously-treated patients with advanced, non-squamous non-small cell lung cancer. Biotech analyst Mark Schoenebaum reportedly said Bristol-Myers' data from its Checkmate 057 study opens the door for lung cancer competition from Merck (MRK) and Roche (RHHBY), according to TheStreet's Adam Feuerstein. INDEXES: The Dow dropped 115.44, or 0.64%, to 18,010.68, the Nasdaq lost 27.95, or 0.55%, to 5,070.03, and the S&P 500 fell 13.40, or 0.63%, to 0.63.
14:58 EDTMRKBristol-Myers Opdivo data opens door for competition, Schoenebaum says
Subscribe for More Information
14:12 EDTMRKMerck: KEYTRUDA monotherapy achieved ORR of 25% in heavily pre-treated patients
Subscribe for More Information
14:08 EDTMRKMerck to initiate Phase 2 study with KEYTRUDA to evaluate MMR-deficiency
Subscribe for More Information
13:36 EDTMRKMerck to hold an investor event with a conference call hookup
In conjunction with ASCO's Annual Meeting, management discusses the company's presentation at ASCO at an Investor Event being held in Chicago on June 1 at 8:30 pm. Webcast Link
08:32 EDTMRKAmgen and Merck expand collaboration to study talimogene laherparepvec
Subscribe for More Information
May 28, 2015
16:31 EDTMRKMerck submits NDA for Grazoprevir/Elbasvir
Subscribe for More Information
08:31 EDTMRKMerck, NanoString announce clinical research collaboration
Subscribe for More Information
May 27, 2015
05:49 EDTMRKStocks with implied volatility movement; MRK EFA
Stocks with implied volatility movement; Merck (MRK) 19, iShares MSCI EAFE Index Fund (EFA) 16 according to iVolatility.
May 26, 2015
16:01 EDTMRKOptions Update; May 26, 2015
Subscribe for More Information
06:36 EDTMRKMerck announces Simponi received CHMP positive opinion
MSD, known as Merck & Co., in the U.S. and Canada, announced that SIMPONI has received CHMP positive opinion for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein, or CRP, and/or magnetic resonance imaging evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs. Once the EU commission issues their EC decision, and if approved, nr-axial SpA patients can be considered for the once-monthly subcutaneous injection with SIMPONI.
May 22, 2015
10:52 EDTMRKJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
07:22 EDTMRKMerck receives positive CHMP opinion for Pembrolizumab in advanced melanoma
Subscribe for More Information
07:15 EDTMRKMerck receives positive CHMP opinion for KEYTRUDA in advanced melanoma
Merck announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion recommending approval of KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of advanced melanoma, as both first-line therapy and in previously treated patients. The CHMP positive opinion for KEYTRUDA, which is based on data in more than 1,500 adult patients with advanced melanoma, will now be reviewed by the European Commission for central marketing authorization in the European Union.
May 19, 2015
07:28 EDTMRKUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
06:55 EDTMRKGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use